Hummingbird Capital Initiates Coverage on NanoViricides Inc. (NYSE: NNVC) – Monitoring Broad-Spectrum Antiviral Potential & Short Squeeze Setup

oronto, ON, Canada – January 16, 2026 – Hummingbird Capital Inc. is pleased to announce it has initiated coverage on NanoViricides Inc. (NYSE: NNVC), a clinical-stage nano-biopharmaceutical company developing a novel class of broad-spectrum antiviral drugs using its proprietary nanoviricide platform.

With lead candidate NV-387 advancing toward Phase 2 human trials (targeting MPox, respiratory viruses including influenza/RSV/coronaviruses, and potential biodefense applications), NNVC is positioned in a critical area of global health. Analyst commentary (e.g., Zacks Small Cap Research) has recently highlighted a $7 valuation potential, driven by NV-387’s mutation-resistant mechanism, strong preclinical data, and pathways to U.S. Strategic National Stockpile inclusion or BARDA funding.

The company’s platform mimics human cell receptors to bind, trap, and dismantle viruses before infection — a resistance-proof approach with broad potential across seasonal epidemics, emerging threats, and biodefense. Recent measles resurgence and orthopoxvirus concerns further underscore the need for such therapeutics.

Short Squeeze Potential Indicators

• Low float and elevated short interest create classic conditions for rapid momentum on positive catalysts (e.g., trial updates, funding announcements).

• Recent market attention to similar setups (e.g., NYSE:AGH and NASDAQ:VWAV in 2025) highlights how visibility and buying pressure can shift dynamics quickly.

Hummingbird will deploy its targeted investor awareness and strategic outreach program to enhance visibility, broaden the shareholder base, and support momentum for NNVC in this high-impact space.

We look forward to tracking NNVC’s progress as it advances toward Phase 2 and potential regulatory/commercial milestones.

About NanoViricides Inc. (NNVC) NanoViricides Inc. (NYSE: NNVC) is a clinical-stage company developing a novel class of broad-spectrum antiviral drugs called nanoviricides. These agents mimic cell surface receptors to bind, trap, and dismantle viruses before they infect host cells. Lead candidate NV-387 is advancing toward Phase 2 trials for MPox, respiratory viruses (influenza, RSV, coronaviruses), and biodefense indications, with potential for mutation-proof efficacy and applications in seasonal epidemics and global health threats.

About Hummingbird Capital Inc. Headquartered in Toronto, Canada with offices in The Bahamas, Hummingbird Capital is an advisory and private boutique investment banking firm specializing in performance-aligned solutions for undervalued public companies. We deliver short defense strategies, investor awareness and relations programs, capital raising advisory, and uplisting guidance.

Hummingbird Capital Inc.

100 King Street West

Suite 5700, Toronto ON  M5X 1C7

t. +1 416 640-9822 ext 321

X. @hummingbirdcap1

www.hummingbird-capital.com

Disclaimer Nothing in this website, presentation, communication, or email constitutes an offer or solicitation to invest in securities of any kind nor does it constitute any investment advice. Short squeeze or breakout potential is speculative and based on public data; actual results may vary significantly. Investors should conduct their own due diligence. Hummingbird Capital Inc. is not responsible for any investment decisions based on this information.